nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—TXK—lung cancer	0.0975	0.297	CbGaD
Dasatinib—FGR—lung cancer	0.0739	0.225	CbGaD
Dasatinib—ERBB3—lung cancer	0.0526	0.16	CbGaD
Dasatinib—SRC—lung cancer	0.0351	0.107	CbGaD
Dasatinib—KIT—lung cancer	0.0311	0.0949	CbGaD
Dasatinib—TESK1—Crizotinib—lung cancer	0.0223	0.0516	CbGbCtD
Dasatinib—ERBB3—Gefitinib—lung cancer	0.0209	0.0483	CbGbCtD
Dasatinib—ABCG2—lung cancer	0.0172	0.0525	CbGaD
Dasatinib—RIPK2—Crizotinib—lung cancer	0.0161	0.0373	CbGbCtD
Dasatinib—TXK—Crizotinib—lung cancer	0.0161	0.0373	CbGbCtD
Dasatinib—LIMK2—Crizotinib—lung cancer	0.0161	0.0373	CbGbCtD
Dasatinib—SIK2—Crizotinib—lung cancer	0.0161	0.0373	CbGbCtD
Dasatinib—CYP1A1—lung cancer	0.0135	0.0412	CbGaD
Dasatinib—STK35—Crizotinib—lung cancer	0.0128	0.0296	CbGbCtD
Dasatinib—EPHA5—Crizotinib—lung cancer	0.0128	0.0296	CbGbCtD
Dasatinib—JAK2—Crizotinib—lung cancer	0.0128	0.0296	CbGbCtD
Dasatinib—EPHA4—Crizotinib—lung cancer	0.0128	0.0296	CbGbCtD
Dasatinib—TNK2—Crizotinib—lung cancer	0.0128	0.0296	CbGbCtD
Dasatinib—BMPR1B—Crizotinib—lung cancer	0.0128	0.0296	CbGbCtD
Dasatinib—EPHB4—Crizotinib—lung cancer	0.0128	0.0296	CbGbCtD
Dasatinib—EPHA3—Crizotinib—lung cancer	0.0128	0.0296	CbGbCtD
Dasatinib—MAP2K5—Gefitinib—lung cancer	0.0109	0.0253	CbGbCtD
Dasatinib—EPHA2—Crizotinib—lung cancer	0.0107	0.0248	CbGbCtD
Dasatinib—EPHA8—Crizotinib—lung cancer	0.0107	0.0248	CbGbCtD
Dasatinib—MAP4K5—Crizotinib—lung cancer	0.0107	0.0248	CbGbCtD
Dasatinib—MAP3K3—Crizotinib—lung cancer	0.0107	0.0248	CbGbCtD
Dasatinib—YES1—Crizotinib—lung cancer	0.0107	0.0248	CbGbCtD
Dasatinib—MAP3K19—Gefitinib—lung cancer	0.01	0.0232	CbGbCtD
Dasatinib—MAP3K2—Crizotinib—lung cancer	0.00926	0.0214	CbGbCtD
Dasatinib—FGR—Crizotinib—lung cancer	0.00926	0.0214	CbGbCtD
Dasatinib—LYN—Crizotinib—lung cancer	0.00819	0.0189	CbGbCtD
Dasatinib—BLK—Crizotinib—lung cancer	0.00819	0.0189	CbGbCtD
Dasatinib—SRC—Crizotinib—lung cancer	0.00819	0.0189	CbGbCtD
Dasatinib—EPHB6—Crizotinib—lung cancer	0.00819	0.0189	CbGbCtD
Dasatinib—ABL2—Crizotinib—lung cancer	0.00736	0.017	CbGbCtD
Dasatinib—CSF1R—Crizotinib—lung cancer	0.00736	0.017	CbGbCtD
Dasatinib—ABCB1—lung cancer	0.00718	0.0219	CbGaD
Dasatinib—ABL2—Erlotinib—lung cancer	0.0071	0.0164	CbGbCtD
Dasatinib—LCK—Crizotinib—lung cancer	0.0067	0.0155	CbGbCtD
Dasatinib—MAP2K5—Erlotinib—lung cancer	0.00646	0.0149	CbGbCtD
Dasatinib—MAP3K19—Crizotinib—lung cancer	0.00616	0.0142	CbGbCtD
Dasatinib—MAP3K19—Erlotinib—lung cancer	0.00594	0.0137	CbGbCtD
Dasatinib—ABL1—Crizotinib—lung cancer	0.00532	0.0123	CbGbCtD
Dasatinib—ABL1—Erlotinib—lung cancer	0.00513	0.0119	CbGbCtD
Dasatinib—CYP1B1—Erlotinib—lung cancer	0.00247	0.0057	CbGbCtD
Dasatinib—CYP1B1—Paclitaxel—lung cancer	0.00226	0.00522	CbGbCtD
Dasatinib—ABCG2—Topotecan—lung cancer	0.00217	0.00501	CbGbCtD
Dasatinib—ABCG2—Gefitinib—lung cancer	0.00198	0.00458	CbGbCtD
Dasatinib—ABCG2—Teniposide—lung cancer	0.00192	0.00445	CbGbCtD
Dasatinib—CYP1A1—Gefitinib—lung cancer	0.00183	0.00423	CbGbCtD
Dasatinib—CYP1B1—Docetaxel—lung cancer	0.00163	0.00377	CbGbCtD
Dasatinib—CYP1B1—Doxorubicin—lung cancer	0.00122	0.00281	CbGbCtD
Dasatinib—ABCG2—Erlotinib—lung cancer	0.00117	0.00271	CbGbCtD
Dasatinib—CYP3A5—Gefitinib—lung cancer	0.0011	0.00254	CbGbCtD
Dasatinib—CYP1A1—Erlotinib—lung cancer	0.00108	0.0025	CbGbCtD
Dasatinib—ABCG2—Paclitaxel—lung cancer	0.00107	0.00248	CbGbCtD
Dasatinib—CYP3A5—Teniposide—lung cancer	0.00107	0.00246	CbGbCtD
Dasatinib—ABCG2—Irinotecan—lung cancer	0.00106	0.00245	CbGbCtD
Dasatinib—ABCG2—Cisplatin—lung cancer	0.000863	0.002	CbGbCtD
Dasatinib—ABCG2—Etoposide—lung cancer	0.000848	0.00196	CbGbCtD
Dasatinib—ABCB1—Topotecan—lung cancer	0.000782	0.00181	CbGbCtD
Dasatinib—ABCG2—Docetaxel—lung cancer	0.000776	0.00179	CbGbCtD
Dasatinib—ABCB1—Gefitinib—lung cancer	0.000715	0.00165	CbGbCtD
Dasatinib—CYP3A5—Crizotinib—lung cancer	0.000673	0.00156	CbGbCtD
Dasatinib—CYP3A5—Erlotinib—lung cancer	0.000649	0.0015	CbGbCtD
Dasatinib—EPHB2—Irinotecan—Topotecan—lung cancer	0.000641	0.381	CbGdCrCtD
Dasatinib—CYP3A5—Paclitaxel—lung cancer	0.000594	0.00137	CbGbCtD
Dasatinib—CYP3A5—Irinotecan—lung cancer	0.000586	0.00136	CbGbCtD
Dasatinib—ABCG2—Doxorubicin—lung cancer	0.000578	0.00134	CbGbCtD
Dasatinib—ABCG2—Methotrexate—lung cancer	0.00056	0.0013	CbGbCtD
Dasatinib—ABCB1—Vinorelbine—lung cancer	0.000551	0.00127	CbGbCtD
Dasatinib—CYP1A2—Erlotinib—lung cancer	0.000483	0.00112	CbGbCtD
Dasatinib—CYP3A5—Etoposide—lung cancer	0.00047	0.00109	CbGbCtD
Dasatinib—CYP3A4—Topotecan—lung cancer	0.000468	0.00108	CbGbCtD
Dasatinib—ABCB1—Crizotinib—lung cancer	0.000438	0.00101	CbGbCtD
Dasatinib—CYP3A5—Docetaxel—lung cancer	0.00043	0.000994	CbGbCtD
Dasatinib—CYP3A4—Gefitinib—lung cancer	0.000428	0.00099	CbGbCtD
Dasatinib—ABCB1—Gemcitabine—lung cancer	0.000428	0.00099	CbGbCtD
Dasatinib—ABCB1—Erlotinib—lung cancer	0.000423	0.000977	CbGbCtD
Dasatinib—CYP3A4—Teniposide—lung cancer	0.000415	0.00096	CbGbCtD
Dasatinib—ABCB1—Paclitaxel—lung cancer	0.000387	0.000895	CbGbCtD
Dasatinib—ABCB1—Irinotecan—lung cancer	0.000382	0.000883	CbGbCtD
Dasatinib—PTK6—bronchus—lung cancer	0.000374	0.00771	CbGeAlD
Dasatinib—ZAK—respiratory system—lung cancer	0.000359	0.00741	CbGeAlD
Dasatinib—STAT5B—epithelium—lung cancer	0.000359	0.0074	CbGeAlD
Dasatinib—CYP1A2—Etoposide—lung cancer	0.00035	0.000808	CbGbCtD
Dasatinib—MAP3K19—respiratory system—lung cancer	0.000344	0.0071	CbGeAlD
Dasatinib—JAK2—mammary gland—lung cancer	0.00034	0.00701	CbGeAlD
Dasatinib—ABCB1—Vinblastine—lung cancer	0.000339	0.000785	CbGbCtD
Dasatinib—EPHA2—mammary gland—lung cancer	0.000336	0.00692	CbGeAlD
Dasatinib—PTK6—trachea—lung cancer	0.000336	0.00692	CbGeAlD
Dasatinib—CYP3A4—Vinorelbine—lung cancer	0.00033	0.000763	CbGbCtD
Dasatinib—MAP3K3—mammary gland—lung cancer	0.000328	0.00675	CbGeAlD
Dasatinib—ABCB1—Cisplatin—lung cancer	0.000311	0.00072	CbGbCtD
Dasatinib—ABCB1—Etoposide—lung cancer	0.000306	0.000707	CbGbCtD
Dasatinib—YES1—mammary gland—lung cancer	0.000303	0.00624	CbGeAlD
Dasatinib—LIMK2—respiratory system—lung cancer	0.000302	0.00623	CbGeAlD
Dasatinib—PDGFRA—mammary gland—lung cancer	0.000297	0.00612	CbGeAlD
Dasatinib—ZAK—bronchus—lung cancer	0.000296	0.00609	CbGeAlD
Dasatinib—PKMYT1—bone marrow—lung cancer	0.000291	0.006	CbGeAlD
Dasatinib—CSK—respiratory system—lung cancer	0.000291	0.006	CbGeAlD
Dasatinib—BMPR1B—epithelium—lung cancer	0.000288	0.00593	CbGeAlD
Dasatinib—BMX—bone marrow—lung cancer	0.000284	0.00586	CbGeAlD
Dasatinib—BMPR1B—bronchus—lung cancer	0.000283	0.00584	CbGeAlD
Dasatinib—BTK—bronchus—lung cancer	0.000282	0.00581	CbGeAlD
Dasatinib—ABCB1—Docetaxel—lung cancer	0.00028	0.000647	CbGbCtD
Dasatinib—SRMS—bone marrow—lung cancer	0.000272	0.0056	CbGeAlD
Dasatinib—TXK—bone marrow—lung cancer	0.000269	0.00555	CbGeAlD
Dasatinib—SIK3—cardiac atrium—lung cancer	0.000268	0.00553	CbGeAlD
Dasatinib—TEC—lymph node—lung cancer	0.000267	0.00551	CbGeAlD
Dasatinib—SIK1—respiratory system—lung cancer	0.000264	0.00544	CbGeAlD
Dasatinib—CYP3A4—Crizotinib—lung cancer	0.000263	0.000607	CbGbCtD
Dasatinib—TESK1—bronchus—lung cancer	0.000261	0.00539	CbGeAlD
Dasatinib—CSF1R—mammary gland—lung cancer	0.000261	0.00539	CbGeAlD
Dasatinib—ERBB3—respiratory system—lung cancer	0.000258	0.00533	CbGeAlD
Dasatinib—BMX—lung—lung cancer	0.000257	0.00531	CbGeAlD
Dasatinib—STK36—bronchus—lung cancer	0.000257	0.0053	CbGeAlD
Dasatinib—EPHB3—bronchus—lung cancer	0.000257	0.0053	CbGeAlD
Dasatinib—CYP3A4—Erlotinib—lung cancer	0.000253	0.000586	CbGbCtD
Dasatinib—STAT5B—bone marrow—lung cancer	0.000252	0.00519	CbGeAlD
Dasatinib—LIMK2—bronchus—lung cancer	0.000249	0.00513	CbGeAlD
Dasatinib—PKMYT1—Afatinib—Gefitinib—lung cancer	0.000247	0.147	CbGdCrCtD
Dasatinib—SRMS—lung—lung cancer	0.000246	0.00508	CbGeAlD
Dasatinib—TXK—lung—lung cancer	0.000244	0.00502	CbGeAlD
Dasatinib—PTK6—lung—lung cancer	0.000241	0.00497	CbGeAlD
Dasatinib—MAPK14—respiratory system—lung cancer	0.000241	0.00496	CbGeAlD
Dasatinib—FGR—respiratory system—lung cancer	0.00024	0.00494	CbGeAlD
Dasatinib—CSK—bronchus—lung cancer	0.000239	0.00494	CbGeAlD
Dasatinib—KIT—mammary gland—lung cancer	0.000237	0.00489	CbGeAlD
Dasatinib—HCK—bronchus—lung cancer	0.000236	0.00487	CbGeAlD
Dasatinib—TESK1—trachea—lung cancer	0.000235	0.00484	CbGeAlD
Dasatinib—CYP3A4—Paclitaxel—lung cancer	0.000232	0.000536	CbGbCtD
Dasatinib—PDGFRB—mammary gland—lung cancer	0.000232	0.00478	CbGeAlD
Dasatinib—FMO3—respiratory system—lung cancer	0.000231	0.00477	CbGeAlD
Dasatinib—STK36—trachea—lung cancer	0.000231	0.00476	CbGeAlD
Dasatinib—EPHB3—trachea—lung cancer	0.000231	0.00476	CbGeAlD
Dasatinib—CYP3A4—Irinotecan—lung cancer	0.000229	0.000529	CbGbCtD
Dasatinib—STAT5B—lung—lung cancer	0.000228	0.0047	CbGeAlD
Dasatinib—EPHB4—respiratory system—lung cancer	0.000228	0.0047	CbGeAlD
Dasatinib—JAK2—respiratory system—lung cancer	0.000227	0.00467	CbGeAlD
Dasatinib—RIPK2—epithelium—lung cancer	0.000226	0.00465	CbGeAlD
Dasatinib—EPHA2—respiratory system—lung cancer	0.000224	0.00461	CbGeAlD
Dasatinib—FYN—respiratory system—lung cancer	0.000223	0.00461	CbGeAlD
Dasatinib—LIMK2—trachea—lung cancer	0.000223	0.0046	CbGeAlD
Dasatinib—RIPK2—bronchus—lung cancer	0.000222	0.00458	CbGeAlD
Dasatinib—TESK1—cardiac atrium—lung cancer	0.00022	0.00454	CbGeAlD
Dasatinib—SIK1—bronchus—lung cancer	0.000217	0.00447	CbGeAlD
Dasatinib—ERBB3—epithelium—lung cancer	0.000216	0.00445	CbGeAlD
Dasatinib—CSK—trachea—lung cancer	0.000215	0.00443	CbGeAlD
Dasatinib—EPHA4—bronchus—lung cancer	0.000215	0.00443	CbGeAlD
Dasatinib—HCK—trachea—lung cancer	0.000212	0.00437	CbGeAlD
Dasatinib—EPHA3—lung—lung cancer	0.000211	0.00435	CbGeAlD
Dasatinib—EPHB1—lymph node—lung cancer	0.00021	0.00432	CbGeAlD
Dasatinib—ABCB1—Doxorubicin—lung cancer	0.000209	0.000482	CbGbCtD
Dasatinib—ABL1—mammary gland—lung cancer	0.000207	0.00426	CbGeAlD
Dasatinib—SIK3—lung—lung cancer	0.000205	0.00423	CbGeAlD
Dasatinib—CYP3A4—Vinblastine—lung cancer	0.000203	0.00047	CbGbCtD
Dasatinib—STK35—cardiac atrium—lung cancer	0.000203	0.00419	CbGeAlD
Dasatinib—ABCB1—Methotrexate—lung cancer	0.000202	0.000467	CbGbCtD
Dasatinib—CSK—cardiac atrium—lung cancer	0.000202	0.00416	CbGeAlD
Dasatinib—YES1—respiratory system—lung cancer	0.000202	0.00416	CbGeAlD
Dasatinib—MAPK14—epithelium—lung cancer	0.000201	0.00415	CbGeAlD
Dasatinib—BTK—bone marrow—lung cancer	0.000201	0.00414	CbGeAlD
Dasatinib—RIPK2—trachea—lung cancer	0.0002	0.00411	CbGeAlD
Dasatinib—MAPK14—bronchus—lung cancer	0.000198	0.00408	CbGeAlD
Dasatinib—PDGFRA—respiratory system—lung cancer	0.000198	0.00408	CbGeAlD
Dasatinib—LCK—bronchus—lung cancer	0.000197	0.00407	CbGeAlD
Dasatinib—ERBB3—Podofilox—Teniposide—lung cancer	0.000197	0.117	CbGdCrCtD
Dasatinib—SRC—respiratory system—lung cancer	0.000194	0.004	CbGeAlD
Dasatinib—EPHA4—trachea—lung cancer	0.000193	0.00398	CbGeAlD
Dasatinib—ERBB3—trachea—lung cancer	0.000191	0.00394	CbGeAlD
Dasatinib—ZAK—lung—lung cancer	0.000191	0.00393	CbGeAlD
Dasatinib—EPHB4—epithelium—lung cancer	0.000191	0.00393	CbGeAlD
Dasatinib—FMO3—bronchus—lung cancer	0.000191	0.00393	CbGeAlD
Dasatinib—JAK2—epithelium—lung cancer	0.000189	0.0039	CbGeAlD
Dasatinib—EPHB4—bronchus—lung cancer	0.000188	0.00387	CbGeAlD
Dasatinib—RIPK2—cardiac atrium—lung cancer	0.000187	0.00386	CbGeAlD
Dasatinib—EPHA2—epithelium—lung cancer	0.000187	0.00386	CbGeAlD
Dasatinib—JAK2—bronchus—lung cancer	0.000186	0.00384	CbGeAlD
Dasatinib—EPHA2—bronchus—lung cancer	0.000184	0.0038	CbGeAlD
Dasatinib—FYN—bronchus—lung cancer	0.000184	0.00379	CbGeAlD
Dasatinib—CYP3A4—Etoposide—lung cancer	0.000183	0.000424	CbGbCtD
Dasatinib—SIK1—cardiac atrium—lung cancer	0.000183	0.00377	CbGeAlD
Dasatinib—MAP3K19—lung—lung cancer	0.000183	0.00377	CbGeAlD
Dasatinib—BMPR1B—lung—lung cancer	0.000183	0.00377	CbGeAlD
Dasatinib—BTK—lung—lung cancer	0.000182	0.00375	CbGeAlD
Dasatinib—EPHA4—cardiac atrium—lung cancer	0.000181	0.00374	CbGeAlD
Dasatinib—MAP3K3—bronchus—lung cancer	0.00018	0.0037	CbGeAlD
Dasatinib—MAP4K5—bronchus—lung cancer	0.00018	0.0037	CbGeAlD
Dasatinib—TNK2—lung—lung cancer	0.000179	0.0037	CbGeAlD
Dasatinib—LCK—trachea—lung cancer	0.000177	0.00365	CbGeAlD
Dasatinib—BMX—lymph node—lung cancer	0.000176	0.00363	CbGeAlD
Dasatinib—CYP1B1—mammary gland—lung cancer	0.000175	0.00361	CbGeAlD
Dasatinib—CSF1R—respiratory system—lung cancer	0.000174	0.00359	CbGeAlD
Dasatinib—BLK—lymph node—lung cancer	0.000174	0.00359	CbGeAlD
Dasatinib—EPHB6—bronchus—lung cancer	0.000172	0.00354	CbGeAlD
Dasatinib—CSK—bone marrow—lung cancer	0.00017	0.00351	CbGeAlD
Dasatinib—TESK1—lung—lung cancer	0.000169	0.00348	CbGeAlD
Dasatinib—EPHB4—trachea—lung cancer	0.000169	0.00348	CbGeAlD
Dasatinib—HCK—bone marrow—lung cancer	0.000168	0.00347	CbGeAlD
Dasatinib—CYP3A4—Docetaxel—lung cancer	0.000168	0.000388	CbGbCtD
Dasatinib—ABL1—Topotecan—Irinotecan—lung cancer	0.000168	0.0995	CbGdCrCtD
Dasatinib—JAK2—trachea—lung cancer	0.000167	0.00345	CbGeAlD
Dasatinib—TXK—lymph node—lung cancer	0.000167	0.00344	CbGeAlD
Dasatinib—YES1—bronchus—lung cancer	0.000166	0.00342	CbGeAlD
Dasatinib—EPHB3—lung—lung cancer	0.000166	0.00342	CbGeAlD
Dasatinib—STK36—lung—lung cancer	0.000166	0.00342	CbGeAlD
Dasatinib—EPHA2—trachea—lung cancer	0.000165	0.00341	CbGeAlD
Dasatinib—FYN—trachea—lung cancer	0.000165	0.0034	CbGeAlD
Dasatinib—SRC—epithelium—lung cancer	0.000162	0.00334	CbGeAlD
Dasatinib—MAP4K5—trachea—lung cancer	0.000161	0.00333	CbGeAlD
Dasatinib—MAP3K3—trachea—lung cancer	0.000161	0.00333	CbGeAlD
Dasatinib—LIMK2—lung—lung cancer	0.00016	0.00331	CbGeAlD
Dasatinib—EPHB4—cardiac atrium—lung cancer	0.000158	0.00326	CbGeAlD
Dasatinib—RIPK2—bone marrow—lung cancer	0.000158	0.00326	CbGeAlD
Dasatinib—KIT—respiratory system—lung cancer	0.000158	0.00326	CbGeAlD
Dasatinib—JAK2—cardiac atrium—lung cancer	0.000157	0.00324	CbGeAlD
Dasatinib—STAT5B—lymph node—lung cancer	0.000156	0.00322	CbGeAlD
Dasatinib—STK35—lung—lung cancer	0.000155	0.00321	CbGeAlD
Dasatinib—EPHA2—cardiac atrium—lung cancer	0.000155	0.0032	CbGeAlD
Dasatinib—FYN—cardiac atrium—lung cancer	0.000155	0.0032	CbGeAlD
Dasatinib—SIK1—bone marrow—lung cancer	0.000155	0.00319	CbGeAlD
Dasatinib—CSK—lung—lung cancer	0.000154	0.00318	CbGeAlD
Dasatinib—PDGFRB—respiratory system—lung cancer	0.000154	0.00318	CbGeAlD
Dasatinib—EPHB6—trachea—lung cancer	0.000154	0.00318	CbGeAlD
Dasatinib—HCK—lung—lung cancer	0.000152	0.00314	CbGeAlD
Dasatinib—MAP4K5—cardiac atrium—lung cancer	0.000152	0.00312	CbGeAlD
Dasatinib—MAP3K3—cardiac atrium—lung cancer	0.000152	0.00312	CbGeAlD
Dasatinib—ABL2—lung—lung cancer	0.000152	0.00312	CbGeAlD
Dasatinib—MAP3K2—bone marrow—lung cancer	0.00015	0.00309	CbGeAlD
Dasatinib—YES1—trachea—lung cancer	0.000149	0.00307	CbGeAlD
Dasatinib—MAP2K5—bronchus—lung cancer	0.000147	0.00303	CbGeAlD
Dasatinib—PDGFRA—trachea—lung cancer	0.000146	0.00301	CbGeAlD
Dasatinib—EPHB6—cardiac atrium—lung cancer	0.000145	0.00299	CbGeAlD
Dasatinib—EPHA3—lymph node—lung cancer	0.000144	0.00297	CbGeAlD
Dasatinib—RIPK2—lung—lung cancer	0.000143	0.00296	CbGeAlD
Dasatinib—CSF1R—bronchus—lung cancer	0.000143	0.00295	CbGeAlD
Dasatinib—MAPK14—bone marrow—lung cancer	0.000141	0.00291	CbGeAlD
Dasatinib—FGR—bone marrow—lung cancer	0.00014	0.0029	CbGeAlD
Dasatinib—LCK—bone marrow—lung cancer	0.00014	0.0029	CbGeAlD
Dasatinib—SIK3—lymph node—lung cancer	0.00014	0.00289	CbGeAlD
Dasatinib—SIK1—lung—lung cancer	0.00014	0.00289	CbGeAlD
Dasatinib—YES1—cardiac atrium—lung cancer	0.00014	0.00289	CbGeAlD
Dasatinib—EPHA4—lung—lung cancer	0.000139	0.00286	CbGeAlD
Dasatinib—ABL1—respiratory system—lung cancer	0.000138	0.00284	CbGeAlD
Dasatinib—ERBB3—lung—lung cancer	0.000137	0.00283	CbGeAlD
Dasatinib—MAP3K2—lung—lung cancer	0.000136	0.0028	CbGeAlD
Dasatinib—SRC—cardiac atrium—lung cancer	0.000135	0.00278	CbGeAlD
Dasatinib—EPHB4—bone marrow—lung cancer	0.000134	0.00276	CbGeAlD
Dasatinib—JAK2—bone marrow—lung cancer	0.000133	0.00274	CbGeAlD
Dasatinib—KIT—epithelium—lung cancer	0.000132	0.00272	CbGeAlD
Dasatinib—MAP2K5—trachea—lung cancer	0.000132	0.00272	CbGeAlD
Dasatinib—FYN—bone marrow—lung cancer	0.000131	0.0027	CbGeAlD
Dasatinib—ZAK—lymph node—lung cancer	0.00013	0.00269	CbGeAlD
Dasatinib—KIT—bronchus—lung cancer	0.00013	0.00268	CbGeAlD
Dasatinib—PDGFRB—epithelium—lung cancer	0.000129	0.00266	CbGeAlD
Dasatinib—CSF1R—trachea—lung cancer	0.000129	0.00265	CbGeAlD
Dasatinib—MAP3K3—bone marrow—lung cancer	0.000128	0.00264	CbGeAlD
Dasatinib—MAP4K5—bone marrow—lung cancer	0.000128	0.00264	CbGeAlD
Dasatinib—MAPK14—lung—lung cancer	0.000128	0.00263	CbGeAlD
Dasatinib—FGR—lung—lung cancer	0.000127	0.00262	CbGeAlD
Dasatinib—LCK—lung—lung cancer	0.000127	0.00262	CbGeAlD
Dasatinib—PDGFRB—bronchus—lung cancer	0.000127	0.00262	CbGeAlD
Dasatinib—BMPR1B—lymph node—lung cancer	0.000125	0.00258	CbGeAlD
Dasatinib—CYP3A4—Doxorubicin—lung cancer	0.000125	0.000289	CbGbCtD
Dasatinib—BTK—lymph node—lung cancer	0.000124	0.00257	CbGeAlD
Dasatinib—MAP2K5—cardiac atrium—lung cancer	0.000124	0.00255	CbGeAlD
Dasatinib—FMO3—lung—lung cancer	0.000123	0.00253	CbGeAlD
Dasatinib—TNK2—lymph node—lung cancer	0.000123	0.00253	CbGeAlD
Dasatinib—EPHB4—lung—lung cancer	0.000121	0.0025	CbGeAlD
Dasatinib—CSF1R—cardiac atrium—lung cancer	0.000121	0.00249	CbGeAlD
Dasatinib—JAK2—lung—lung cancer	0.00012	0.00248	CbGeAlD
Dasatinib—EPHA2—lung—lung cancer	0.000119	0.00245	CbGeAlD
Dasatinib—FYN—lung—lung cancer	0.000119	0.00245	CbGeAlD
Dasatinib—YES1—bone marrow—lung cancer	0.000118	0.00244	CbGeAlD
Dasatinib—ERBB3—Podofilox—Etoposide—lung cancer	0.000117	0.0696	CbGdCrCtD
Dasatinib—KIT—trachea—lung cancer	0.000117	0.00241	CbGeAlD
Dasatinib—CYP1B1—respiratory system—lung cancer	0.000117	0.0024	CbGeAlD
Dasatinib—MAP4K5—lung—lung cancer	0.000116	0.00239	CbGeAlD
Dasatinib—MAP3K3—lung—lung cancer	0.000116	0.00239	CbGeAlD
Dasatinib—TESK1—lymph node—lung cancer	0.000115	0.00238	CbGeAlD
Dasatinib—PDGFRB—trachea—lung cancer	0.000114	0.00235	CbGeAlD
Dasatinib—STK36—lymph node—lung cancer	0.000113	0.00234	CbGeAlD
Dasatinib—EPHB3—lymph node—lung cancer	0.000113	0.00234	CbGeAlD
Dasatinib—ABL1—bronchus—lung cancer	0.000113	0.00234	CbGeAlD
Dasatinib—EPHB6—lung—lung cancer	0.000111	0.00228	CbGeAlD
Dasatinib—LIMK2—lymph node—lung cancer	0.00011	0.00226	CbGeAlD
Dasatinib—PDGFRB—cardiac atrium—lung cancer	0.000107	0.00221	CbGeAlD
Dasatinib—YES1—lung—lung cancer	0.000107	0.00221	CbGeAlD
Dasatinib—STK35—lymph node—lung cancer	0.000106	0.00219	CbGeAlD
Dasatinib—CSK—lymph node—lung cancer	0.000106	0.00218	CbGeAlD
Dasatinib—PDGFRA—lung—lung cancer	0.000105	0.00217	CbGeAlD
Dasatinib—HCK—lymph node—lung cancer	0.000104	0.00215	CbGeAlD
Dasatinib—ABL2—lymph node—lung cancer	0.000104	0.00214	CbGeAlD
Dasatinib—SRC—lung—lung cancer	0.000103	0.00212	CbGeAlD
Dasatinib—CSF1R—bone marrow—lung cancer	0.000102	0.0021	CbGeAlD
Dasatinib—ABL1—trachea—lung cancer	0.000102	0.0021	CbGeAlD
Dasatinib—ERBB3—Vinblastine—Vinorelbine—lung cancer	0.000101	0.0599	CbGdCrCtD
Dasatinib—RIPK2—lymph node—lung cancer	9.81e-05	0.00202	CbGeAlD
Dasatinib—SIK1—lymph node—lung cancer	9.57e-05	0.00197	CbGeAlD
Dasatinib—ABL1—cardiac atrium—lung cancer	9.56e-05	0.00197	CbGeAlD
Dasatinib—EPHA4—lymph node—lung cancer	9.48e-05	0.00195	CbGeAlD
Dasatinib—MAP2K5—lung—lung cancer	9.47e-05	0.00195	CbGeAlD
Dasatinib—ERBB3—lymph node—lung cancer	9.39e-05	0.00193	CbGeAlD
Dasatinib—MAP3K2—lymph node—lung cancer	9.3e-05	0.00192	CbGeAlD
Dasatinib—KIT—bone marrow—lung cancer	9.27e-05	0.00191	CbGeAlD
Dasatinib—CSF1R—lung—lung cancer	9.25e-05	0.00191	CbGeAlD
Dasatinib—PDGFRB—bone marrow—lung cancer	9.05e-05	0.00187	CbGeAlD
Dasatinib—MAPK14—lymph node—lung cancer	8.74e-05	0.0018	CbGeAlD
Dasatinib—FGR—lymph node—lung cancer	8.7e-05	0.00179	CbGeAlD
Dasatinib—LCK—lymph node—lung cancer	8.7e-05	0.00179	CbGeAlD
Dasatinib—FMO3—lymph node—lung cancer	8.41e-05	0.00173	CbGeAlD
Dasatinib—KIT—lung—lung cancer	8.4e-05	0.00173	CbGeAlD
Dasatinib—CYP1A2—respiratory system—lung cancer	8.35e-05	0.00172	CbGeAlD
Dasatinib—EPHB4—lymph node—lung cancer	8.28e-05	0.00171	CbGeAlD
Dasatinib—CYP1A1—respiratory system—lung cancer	8.24e-05	0.0017	CbGeAlD
Dasatinib—JAK2—lymph node—lung cancer	8.23e-05	0.0017	CbGeAlD
Dasatinib—PDGFRB—lung—lung cancer	8.2e-05	0.00169	CbGeAlD
Dasatinib—EPHA2—lymph node—lung cancer	8.13e-05	0.00168	CbGeAlD
Dasatinib—FYN—lymph node—lung cancer	8.11e-05	0.00167	CbGeAlD
Dasatinib—ABL1—bone marrow—lung cancer	8.07e-05	0.00166	CbGeAlD
Dasatinib—CYP3A5—respiratory system—lung cancer	8.06e-05	0.00166	CbGeAlD
Dasatinib—MAP4K5—lymph node—lung cancer	7.93e-05	0.00163	CbGeAlD
Dasatinib—MAP3K3—lymph node—lung cancer	7.93e-05	0.00163	CbGeAlD
Dasatinib—EPHB6—lymph node—lung cancer	7.58e-05	0.00156	CbGeAlD
Dasatinib—YES1—lymph node—lung cancer	7.32e-05	0.00151	CbGeAlD
Dasatinib—ABL1—lung—lung cancer	7.31e-05	0.00151	CbGeAlD
Dasatinib—PDGFRA—lymph node—lung cancer	7.18e-05	0.00148	CbGeAlD
Dasatinib—SRC—lymph node—lung cancer	7.04e-05	0.00145	CbGeAlD
Dasatinib—CYP1A1—epithelium—lung cancer	6.89e-05	0.00142	CbGeAlD
Dasatinib—CYP1A1—bronchus—lung cancer	6.78e-05	0.0014	CbGeAlD
Dasatinib—MAP2K5—lymph node—lung cancer	6.48e-05	0.00134	CbGeAlD
Dasatinib—CSF1R—lymph node—lung cancer	6.32e-05	0.0013	CbGeAlD
Dasatinib—CYP1B1—lung—lung cancer	6.19e-05	0.00128	CbGeAlD
Dasatinib—CYP1A1—trachea—lung cancer	6.09e-05	0.00126	CbGeAlD
Dasatinib—KIT—lymph node—lung cancer	5.74e-05	0.00118	CbGeAlD
Dasatinib—CYP1A1—cardiac atrium—lung cancer	5.72e-05	0.00118	CbGeAlD
Dasatinib—PDGFRB—lymph node—lung cancer	5.61e-05	0.00116	CbGeAlD
Dasatinib—CSK—Daunorubicin—Doxorubicin—lung cancer	5.22e-05	0.031	CbGdCrCtD
Dasatinib—CSK—Epirubicin—Doxorubicin—lung cancer	5.22e-05	0.031	CbGdCrCtD
Dasatinib—ABCG2—bone marrow—lung cancer	5.09e-05	0.00105	CbGeAlD
Dasatinib—ABL1—lymph node—lung cancer	5e-05	0.00103	CbGeAlD
Dasatinib—ABCG2—lung—lung cancer	4.61e-05	0.00095	CbGeAlD
Dasatinib—CYP1A2—lung—lung cancer	4.44e-05	0.000915	CbGeAlD
Dasatinib—CYP1A1—lung—lung cancer	4.38e-05	0.000902	CbGeAlD
Dasatinib—ABCB1—respiratory system—lung cancer	4.28e-05	0.000882	CbGeAlD
Dasatinib—CYP3A5—lung—lung cancer	4.28e-05	0.000882	CbGeAlD
Dasatinib—CYP1B1—lymph node—lung cancer	4.23e-05	0.000873	CbGeAlD
Dasatinib—ABL1—Idarubicin—Doxorubicin—lung cancer	3.65e-05	0.0216	CbGdCrCtD
Dasatinib—ABL1—Epirubicin—Doxorubicin—lung cancer	3.65e-05	0.0216	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—lung cancer	3.65e-05	0.0216	CbGdCrCtD
Dasatinib—ABCB1—epithelium—lung cancer	3.58e-05	0.000737	CbGeAlD
Dasatinib—ABCB1—trachea—lung cancer	3.16e-05	0.000652	CbGeAlD
Dasatinib—ABCG2—lymph node—lung cancer	3.15e-05	0.00065	CbGeAlD
Dasatinib—CYP1A1—lymph node—lung cancer	2.99e-05	0.000617	CbGeAlD
Dasatinib—ABCB1—bone marrow—lung cancer	2.51e-05	0.000517	CbGeAlD
Dasatinib—ABCB1—lung—lung cancer	2.27e-05	0.000469	CbGeAlD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	1.89e-05	0.000216	CcSEcCtD
Dasatinib—Pain—Etoposide—lung cancer	1.88e-05	0.000215	CcSEcCtD
Dasatinib—Constipation—Etoposide—lung cancer	1.88e-05	0.000215	CcSEcCtD
Dasatinib—Neutropenia—Doxorubicin—lung cancer	1.87e-05	0.000214	CcSEcCtD
Dasatinib—Decreased appetite—Paclitaxel—lung cancer	1.87e-05	0.000214	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Doxorubicin—lung cancer	1.86e-05	0.000213	CcSEcCtD
Dasatinib—Haemoglobin—Methotrexate—lung cancer	1.86e-05	0.000213	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Paclitaxel—lung cancer	1.86e-05	0.000213	CcSEcCtD
Dasatinib—Fatigue—Paclitaxel—lung cancer	1.86e-05	0.000213	CcSEcCtD
Dasatinib—Haemorrhage—Methotrexate—lung cancer	1.85e-05	0.000212	CcSEcCtD
Dasatinib—Hepatitis—Methotrexate—lung cancer	1.85e-05	0.000212	CcSEcCtD
Dasatinib—Pollakiuria—Doxorubicin—lung cancer	1.85e-05	0.000212	CcSEcCtD
Dasatinib—Asthenia—Gemcitabine—lung cancer	1.84e-05	0.000211	CcSEcCtD
Dasatinib—Pain—Paclitaxel—lung cancer	1.84e-05	0.000211	CcSEcCtD
Dasatinib—Constipation—Paclitaxel—lung cancer	1.84e-05	0.000211	CcSEcCtD
Dasatinib—Confusional state—Docetaxel—lung cancer	1.84e-05	0.000211	CcSEcCtD
Dasatinib—Urinary tract disorder—Methotrexate—lung cancer	1.83e-05	0.000209	CcSEcCtD
Dasatinib—Photosensitivity reaction—Doxorubicin—lung cancer	1.83e-05	0.000209	CcSEcCtD
Dasatinib—Oedema—Docetaxel—lung cancer	1.82e-05	0.000209	CcSEcCtD
Dasatinib—Weight increased—Doxorubicin—lung cancer	1.82e-05	0.000209	CcSEcCtD
Dasatinib—Pruritus—Gemcitabine—lung cancer	1.82e-05	0.000208	CcSEcCtD
Dasatinib—Urethral disorder—Methotrexate—lung cancer	1.81e-05	0.000208	CcSEcCtD
Dasatinib—Infection—Docetaxel—lung cancer	1.81e-05	0.000208	CcSEcCtD
Dasatinib—Weight decreased—Doxorubicin—lung cancer	1.81e-05	0.000207	CcSEcCtD
Dasatinib—Feeling abnormal—Etoposide—lung cancer	1.81e-05	0.000207	CcSEcCtD
Dasatinib—Diarrhoea—Irinotecan—lung cancer	1.81e-05	0.000207	CcSEcCtD
Dasatinib—Pneumonia—Doxorubicin—lung cancer	1.8e-05	0.000206	CcSEcCtD
Dasatinib—Gastrointestinal pain—Etoposide—lung cancer	1.8e-05	0.000206	CcSEcCtD
Dasatinib—Shock—Docetaxel—lung cancer	1.79e-05	0.000206	CcSEcCtD
Dasatinib—Nervous system disorder—Docetaxel—lung cancer	1.79e-05	0.000205	CcSEcCtD
Dasatinib—Thrombocytopenia—Docetaxel—lung cancer	1.79e-05	0.000205	CcSEcCtD
Dasatinib—Infestation NOS—Doxorubicin—lung cancer	1.79e-05	0.000204	CcSEcCtD
Dasatinib—Infestation—Doxorubicin—lung cancer	1.79e-05	0.000204	CcSEcCtD
Dasatinib—Visual impairment—Methotrexate—lung cancer	1.78e-05	0.000204	CcSEcCtD
Dasatinib—Tachycardia—Docetaxel—lung cancer	1.78e-05	0.000204	CcSEcCtD
Dasatinib—Feeling abnormal—Paclitaxel—lung cancer	1.77e-05	0.000203	CcSEcCtD
Dasatinib—Skin disorder—Docetaxel—lung cancer	1.77e-05	0.000203	CcSEcCtD
Dasatinib—Hypersensitivity—Cisplatin—lung cancer	1.77e-05	0.000202	CcSEcCtD
Dasatinib—Gastrointestinal pain—Paclitaxel—lung cancer	1.76e-05	0.000202	CcSEcCtD
Dasatinib—Diarrhoea—Gemcitabine—lung cancer	1.76e-05	0.000201	CcSEcCtD
Dasatinib—Renal failure—Doxorubicin—lung cancer	1.75e-05	0.000201	CcSEcCtD
Dasatinib—Erythema multiforme—Methotrexate—lung cancer	1.75e-05	0.0002	CcSEcCtD
Dasatinib—Neuropathy peripheral—Doxorubicin—lung cancer	1.75e-05	0.0002	CcSEcCtD
Dasatinib—Dizziness—Irinotecan—lung cancer	1.75e-05	0.0002	CcSEcCtD
Dasatinib—Urticaria—Etoposide—lung cancer	1.74e-05	0.0002	CcSEcCtD
Dasatinib—Stomatitis—Doxorubicin—lung cancer	1.74e-05	0.000199	CcSEcCtD
Dasatinib—Anorexia—Docetaxel—lung cancer	1.74e-05	0.000199	CcSEcCtD
Dasatinib—Abdominal pain—Etoposide—lung cancer	1.74e-05	0.000199	CcSEcCtD
Dasatinib—Body temperature increased—Etoposide—lung cancer	1.74e-05	0.000199	CcSEcCtD
Dasatinib—Conjunctivitis—Doxorubicin—lung cancer	1.74e-05	0.000199	CcSEcCtD
Dasatinib—Eye disorder—Methotrexate—lung cancer	1.73e-05	0.000198	CcSEcCtD
Dasatinib—Tinnitus—Methotrexate—lung cancer	1.73e-05	0.000198	CcSEcCtD
Dasatinib—Asthenia—Cisplatin—lung cancer	1.72e-05	0.000197	CcSEcCtD
Dasatinib—Cardiac disorder—Methotrexate—lung cancer	1.72e-05	0.000197	CcSEcCtD
Dasatinib—Urticaria—Paclitaxel—lung cancer	1.71e-05	0.000196	CcSEcCtD
Dasatinib—Hypotension—Docetaxel—lung cancer	1.7e-05	0.000195	CcSEcCtD
Dasatinib—Haematuria—Doxorubicin—lung cancer	1.7e-05	0.000195	CcSEcCtD
Dasatinib—Abdominal pain—Paclitaxel—lung cancer	1.7e-05	0.000195	CcSEcCtD
Dasatinib—Body temperature increased—Paclitaxel—lung cancer	1.7e-05	0.000195	CcSEcCtD
Dasatinib—Hepatobiliary disease—Doxorubicin—lung cancer	1.69e-05	0.000193	CcSEcCtD
Dasatinib—Epistaxis—Doxorubicin—lung cancer	1.68e-05	0.000193	CcSEcCtD
Dasatinib—Angiopathy—Methotrexate—lung cancer	1.68e-05	0.000192	CcSEcCtD
Dasatinib—Vomiting—Irinotecan—lung cancer	1.68e-05	0.000192	CcSEcCtD
Dasatinib—Immune system disorder—Methotrexate—lung cancer	1.67e-05	0.000191	CcSEcCtD
Dasatinib—Mediastinal disorder—Methotrexate—lung cancer	1.67e-05	0.000191	CcSEcCtD
Dasatinib—Rash—Irinotecan—lung cancer	1.66e-05	0.000191	CcSEcCtD
Dasatinib—Dermatitis—Irinotecan—lung cancer	1.66e-05	0.00019	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Docetaxel—lung cancer	1.66e-05	0.00019	CcSEcCtD
Dasatinib—Chills—Methotrexate—lung cancer	1.66e-05	0.00019	CcSEcCtD
Dasatinib—Headache—Irinotecan—lung cancer	1.65e-05	0.000189	CcSEcCtD
Dasatinib—Insomnia—Docetaxel—lung cancer	1.65e-05	0.000189	CcSEcCtD
Dasatinib—Diarrhoea—Cisplatin—lung cancer	1.64e-05	0.000188	CcSEcCtD
Dasatinib—Alopecia—Methotrexate—lung cancer	1.64e-05	0.000187	CcSEcCtD
Dasatinib—Vomiting—Gemcitabine—lung cancer	1.63e-05	0.000187	CcSEcCtD
Dasatinib—Dyspnoea—Docetaxel—lung cancer	1.63e-05	0.000186	CcSEcCtD
Dasatinib—Somnolence—Docetaxel—lung cancer	1.62e-05	0.000186	CcSEcCtD
Dasatinib—Mental disorder—Methotrexate—lung cancer	1.62e-05	0.000186	CcSEcCtD
Dasatinib—Rash—Gemcitabine—lung cancer	1.62e-05	0.000186	CcSEcCtD
Dasatinib—Dermatitis—Gemcitabine—lung cancer	1.62e-05	0.000185	CcSEcCtD
Dasatinib—Hypersensitivity—Etoposide—lung cancer	1.62e-05	0.000185	CcSEcCtD
Dasatinib—Erythema—Methotrexate—lung cancer	1.61e-05	0.000184	CcSEcCtD
Dasatinib—Malnutrition—Methotrexate—lung cancer	1.61e-05	0.000184	CcSEcCtD
Dasatinib—Haemoglobin—Doxorubicin—lung cancer	1.61e-05	0.000184	CcSEcCtD
Dasatinib—Headache—Gemcitabine—lung cancer	1.61e-05	0.000184	CcSEcCtD
Dasatinib—Dyspepsia—Docetaxel—lung cancer	1.61e-05	0.000184	CcSEcCtD
Dasatinib—Hepatitis—Doxorubicin—lung cancer	1.6e-05	0.000184	CcSEcCtD
Dasatinib—Haemorrhage—Doxorubicin—lung cancer	1.6e-05	0.000184	CcSEcCtD
Dasatinib—Decreased appetite—Docetaxel—lung cancer	1.59e-05	0.000182	CcSEcCtD
Dasatinib—Hypersensitivity—Paclitaxel—lung cancer	1.59e-05	0.000182	CcSEcCtD
Dasatinib—Urinary tract disorder—Doxorubicin—lung cancer	1.58e-05	0.000181	CcSEcCtD
Dasatinib—Oedema peripheral—Doxorubicin—lung cancer	1.58e-05	0.000181	CcSEcCtD
Dasatinib—Dysgeusia—Methotrexate—lung cancer	1.58e-05	0.000181	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Docetaxel—lung cancer	1.58e-05	0.00018	CcSEcCtD
Dasatinib—Asthenia—Etoposide—lung cancer	1.58e-05	0.00018	CcSEcCtD
Dasatinib—Connective tissue disorder—Doxorubicin—lung cancer	1.57e-05	0.00018	CcSEcCtD
Dasatinib—Fatigue—Docetaxel—lung cancer	1.57e-05	0.00018	CcSEcCtD
Dasatinib—Urethral disorder—Doxorubicin—lung cancer	1.57e-05	0.00018	CcSEcCtD
Dasatinib—Nausea—Irinotecan—lung cancer	1.57e-05	0.00018	CcSEcCtD
Dasatinib—Constipation—Docetaxel—lung cancer	1.56e-05	0.000179	CcSEcCtD
Dasatinib—Pain—Docetaxel—lung cancer	1.56e-05	0.000179	CcSEcCtD
Dasatinib—ABCB1—lymph node—lung cancer	1.55e-05	0.00032	CbGeAlD
Dasatinib—Pruritus—Etoposide—lung cancer	1.55e-05	0.000178	CcSEcCtD
Dasatinib—Visual impairment—Doxorubicin—lung cancer	1.54e-05	0.000177	CcSEcCtD
Dasatinib—Asthenia—Paclitaxel—lung cancer	1.54e-05	0.000177	CcSEcCtD
Dasatinib—Nausea—Gemcitabine—lung cancer	1.53e-05	0.000175	CcSEcCtD
Dasatinib—Vomiting—Cisplatin—lung cancer	1.52e-05	0.000174	CcSEcCtD
Dasatinib—Pruritus—Paclitaxel—lung cancer	1.52e-05	0.000174	CcSEcCtD
Dasatinib—Vision blurred—Methotrexate—lung cancer	1.52e-05	0.000174	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—lung cancer	1.52e-05	0.000174	CcSEcCtD
Dasatinib—Rash—Cisplatin—lung cancer	1.51e-05	0.000173	CcSEcCtD
Dasatinib—Dermatitis—Cisplatin—lung cancer	1.51e-05	0.000173	CcSEcCtD
Dasatinib—Feeling abnormal—Docetaxel—lung cancer	1.5e-05	0.000172	CcSEcCtD
Dasatinib—Diarrhoea—Etoposide—lung cancer	1.5e-05	0.000172	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—lung cancer	1.5e-05	0.000172	CcSEcCtD
Dasatinib—Ill-defined disorder—Methotrexate—lung cancer	1.49e-05	0.000171	CcSEcCtD
Dasatinib—Tinnitus—Doxorubicin—lung cancer	1.49e-05	0.000171	CcSEcCtD
Dasatinib—Gastrointestinal pain—Docetaxel—lung cancer	1.49e-05	0.000171	CcSEcCtD
Dasatinib—Anaemia—Methotrexate—lung cancer	1.49e-05	0.000171	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—lung cancer	1.49e-05	0.00017	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—lung cancer	1.49e-05	0.00017	CcSEcCtD
Dasatinib—Diarrhoea—Paclitaxel—lung cancer	1.47e-05	0.000169	CcSEcCtD
Dasatinib—Angiopathy—Doxorubicin—lung cancer	1.45e-05	0.000167	CcSEcCtD
Dasatinib—Malaise—Methotrexate—lung cancer	1.45e-05	0.000166	CcSEcCtD
Dasatinib—Dizziness—Etoposide—lung cancer	1.45e-05	0.000166	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—lung cancer	1.45e-05	0.000166	CcSEcCtD
Dasatinib—Vertigo—Methotrexate—lung cancer	1.45e-05	0.000166	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—lung cancer	1.44e-05	0.000165	CcSEcCtD
Dasatinib—Abdominal pain—Docetaxel—lung cancer	1.44e-05	0.000165	CcSEcCtD
Dasatinib—Body temperature increased—Docetaxel—lung cancer	1.44e-05	0.000165	CcSEcCtD
Dasatinib—Chills—Doxorubicin—lung cancer	1.44e-05	0.000165	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—lung cancer	1.43e-05	0.000164	CcSEcCtD
Dasatinib—Dizziness—Paclitaxel—lung cancer	1.42e-05	0.000163	CcSEcCtD
Dasatinib—Nausea—Cisplatin—lung cancer	1.42e-05	0.000163	CcSEcCtD
Dasatinib—Alopecia—Doxorubicin—lung cancer	1.42e-05	0.000162	CcSEcCtD
Dasatinib—Cough—Methotrexate—lung cancer	1.41e-05	0.000161	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—lung cancer	1.4e-05	0.000161	CcSEcCtD
Dasatinib—Convulsion—Methotrexate—lung cancer	1.4e-05	0.00016	CcSEcCtD
Dasatinib—Vomiting—Etoposide—lung cancer	1.4e-05	0.00016	CcSEcCtD
Dasatinib—Erythema—Doxorubicin—lung cancer	1.4e-05	0.00016	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—lung cancer	1.4e-05	0.00016	CcSEcCtD
Dasatinib—Rash—Etoposide—lung cancer	1.38e-05	0.000159	CcSEcCtD
Dasatinib—Dermatitis—Etoposide—lung cancer	1.38e-05	0.000158	CcSEcCtD
Dasatinib—Headache—Etoposide—lung cancer	1.38e-05	0.000157	CcSEcCtD
Dasatinib—Chest pain—Methotrexate—lung cancer	1.37e-05	0.000157	CcSEcCtD
Dasatinib—Myalgia—Methotrexate—lung cancer	1.37e-05	0.000157	CcSEcCtD
Dasatinib—Arthralgia—Methotrexate—lung cancer	1.37e-05	0.000157	CcSEcCtD
Dasatinib—Vomiting—Paclitaxel—lung cancer	1.37e-05	0.000157	CcSEcCtD
Dasatinib—Dysgeusia—Doxorubicin—lung cancer	1.37e-05	0.000156	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	1.36e-05	0.000156	CcSEcCtD
Dasatinib—Rash—Paclitaxel—lung cancer	1.36e-05	0.000155	CcSEcCtD
Dasatinib—Dermatitis—Paclitaxel—lung cancer	1.36e-05	0.000155	CcSEcCtD
Dasatinib—Discomfort—Methotrexate—lung cancer	1.36e-05	0.000155	CcSEcCtD
Dasatinib—Headache—Paclitaxel—lung cancer	1.35e-05	0.000154	CcSEcCtD
Dasatinib—Hypersensitivity—Docetaxel—lung cancer	1.34e-05	0.000154	CcSEcCtD
Dasatinib—Muscle spasms—Doxorubicin—lung cancer	1.34e-05	0.000154	CcSEcCtD
Dasatinib—Confusional state—Methotrexate—lung cancer	1.33e-05	0.000152	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—lung cancer	1.31e-05	0.000151	CcSEcCtD
Dasatinib—Asthenia—Docetaxel—lung cancer	1.31e-05	0.00015	CcSEcCtD
Dasatinib—Infection—Methotrexate—lung cancer	1.31e-05	0.00015	CcSEcCtD
Dasatinib—Nausea—Etoposide—lung cancer	1.3e-05	0.000149	CcSEcCtD
Dasatinib—Ill-defined disorder—Doxorubicin—lung cancer	1.29e-05	0.000148	CcSEcCtD
Dasatinib—Pruritus—Docetaxel—lung cancer	1.29e-05	0.000148	CcSEcCtD
Dasatinib—Nervous system disorder—Methotrexate—lung cancer	1.29e-05	0.000148	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—lung cancer	1.29e-05	0.000148	CcSEcCtD
Dasatinib—Thrombocytopenia—Methotrexate—lung cancer	1.29e-05	0.000147	CcSEcCtD
Dasatinib—Nausea—Paclitaxel—lung cancer	1.28e-05	0.000146	CcSEcCtD
Dasatinib—Skin disorder—Methotrexate—lung cancer	1.28e-05	0.000146	CcSEcCtD
Dasatinib—Hyperhidrosis—Methotrexate—lung cancer	1.27e-05	0.000146	CcSEcCtD
Dasatinib—Malaise—Doxorubicin—lung cancer	1.26e-05	0.000144	CcSEcCtD
Dasatinib—Vertigo—Doxorubicin—lung cancer	1.25e-05	0.000144	CcSEcCtD
Dasatinib—Anorexia—Methotrexate—lung cancer	1.25e-05	0.000144	CcSEcCtD
Dasatinib—Syncope—Doxorubicin—lung cancer	1.25e-05	0.000143	CcSEcCtD
Dasatinib—Diarrhoea—Docetaxel—lung cancer	1.25e-05	0.000143	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—lung cancer	1.23e-05	0.000141	CcSEcCtD
Dasatinib—Hypotension—Methotrexate—lung cancer	1.23e-05	0.000141	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—lung cancer	1.23e-05	0.00014	CcSEcCtD
Dasatinib—Cough—Doxorubicin—lung cancer	1.22e-05	0.000139	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—lung cancer	1.21e-05	0.000138	CcSEcCtD
Dasatinib—Dizziness—Docetaxel—lung cancer	1.21e-05	0.000138	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—lung cancer	1.2e-05	0.000138	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Methotrexate—lung cancer	1.2e-05	0.000137	CcSEcCtD
Dasatinib—Insomnia—Methotrexate—lung cancer	1.19e-05	0.000136	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—lung cancer	1.19e-05	0.000136	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—lung cancer	1.19e-05	0.000136	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—lung cancer	1.19e-05	0.000136	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—lung cancer	1.18e-05	0.000136	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	1.18e-05	0.000135	CcSEcCtD
Dasatinib—Discomfort—Doxorubicin—lung cancer	1.17e-05	0.000134	CcSEcCtD
Dasatinib—Dyspnoea—Methotrexate—lung cancer	1.17e-05	0.000134	CcSEcCtD
Dasatinib—Somnolence—Methotrexate—lung cancer	1.17e-05	0.000134	CcSEcCtD
Dasatinib—Vomiting—Docetaxel—lung cancer	1.16e-05	0.000133	CcSEcCtD
Dasatinib—Dyspepsia—Methotrexate—lung cancer	1.16e-05	0.000133	CcSEcCtD
Dasatinib—Rash—Docetaxel—lung cancer	1.15e-05	0.000132	CcSEcCtD
Dasatinib—Dermatitis—Docetaxel—lung cancer	1.15e-05	0.000132	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—lung cancer	1.15e-05	0.000131	CcSEcCtD
Dasatinib—Decreased appetite—Methotrexate—lung cancer	1.14e-05	0.000131	CcSEcCtD
Dasatinib—Headache—Docetaxel—lung cancer	1.14e-05	0.000131	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—lung cancer	1.14e-05	0.00013	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Methotrexate—lung cancer	1.14e-05	0.00013	CcSEcCtD
Dasatinib—Fatigue—Methotrexate—lung cancer	1.13e-05	0.00013	CcSEcCtD
Dasatinib—Infection—Doxorubicin—lung cancer	1.13e-05	0.00013	CcSEcCtD
Dasatinib—Pain—Methotrexate—lung cancer	1.12e-05	0.000129	CcSEcCtD
Dasatinib—Shock—Doxorubicin—lung cancer	1.12e-05	0.000128	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—lung cancer	1.12e-05	0.000128	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—lung cancer	1.11e-05	0.000128	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—lung cancer	1.11e-05	0.000127	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—lung cancer	1.11e-05	0.000127	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—lung cancer	1.1e-05	0.000126	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—lung cancer	1.09e-05	0.000124	CcSEcCtD
Dasatinib—Nausea—Docetaxel—lung cancer	1.08e-05	0.000124	CcSEcCtD
Dasatinib—Feeling abnormal—Methotrexate—lung cancer	1.08e-05	0.000124	CcSEcCtD
Dasatinib—Gastrointestinal pain—Methotrexate—lung cancer	1.08e-05	0.000123	CcSEcCtD
Dasatinib—Hypotension—Doxorubicin—lung cancer	1.06e-05	0.000122	CcSEcCtD
Dasatinib—Urticaria—Methotrexate—lung cancer	1.04e-05	0.00012	CcSEcCtD
Dasatinib—Abdominal pain—Methotrexate—lung cancer	1.04e-05	0.000119	CcSEcCtD
Dasatinib—Body temperature increased—Methotrexate—lung cancer	1.04e-05	0.000119	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—lung cancer	1.04e-05	0.000119	CcSEcCtD
Dasatinib—Insomnia—Doxorubicin—lung cancer	1.03e-05	0.000118	CcSEcCtD
Dasatinib—Dyspnoea—Doxorubicin—lung cancer	1.02e-05	0.000116	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—lung cancer	1.01e-05	0.000116	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—lung cancer	1e-05	0.000115	CcSEcCtD
Dasatinib—Decreased appetite—Doxorubicin—lung cancer	9.9e-06	0.000113	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Doxorubicin—lung cancer	9.83e-06	0.000113	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—lung cancer	9.82e-06	0.000112	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—lung cancer	9.74e-06	0.000111	CcSEcCtD
Dasatinib—Pain—Doxorubicin—lung cancer	9.74e-06	0.000111	CcSEcCtD
Dasatinib—Hypersensitivity—Methotrexate—lung cancer	9.69e-06	0.000111	CcSEcCtD
Dasatinib—Asthenia—Methotrexate—lung cancer	9.43e-06	0.000108	CcSEcCtD
Dasatinib—Feeling abnormal—Doxorubicin—lung cancer	9.38e-06	0.000107	CcSEcCtD
Dasatinib—Gastrointestinal pain—Doxorubicin—lung cancer	9.31e-06	0.000107	CcSEcCtD
Dasatinib—Pruritus—Methotrexate—lung cancer	9.3e-06	0.000107	CcSEcCtD
Dasatinib—Urticaria—Doxorubicin—lung cancer	9.05e-06	0.000104	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—lung cancer	9e-06	0.000103	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—lung cancer	9e-06	0.000103	CcSEcCtD
Dasatinib—Diarrhoea—Methotrexate—lung cancer	9e-06	0.000103	CcSEcCtD
Dasatinib—Dizziness—Methotrexate—lung cancer	8.7e-06	9.96e-05	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—lung cancer	8.39e-06	9.61e-05	CcSEcCtD
Dasatinib—Vomiting—Methotrexate—lung cancer	8.36e-06	9.57e-05	CcSEcCtD
Dasatinib—Rash—Methotrexate—lung cancer	8.29e-06	9.49e-05	CcSEcCtD
Dasatinib—Dermatitis—Methotrexate—lung cancer	8.28e-06	9.49e-05	CcSEcCtD
Dasatinib—Headache—Methotrexate—lung cancer	8.24e-06	9.43e-05	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—lung cancer	8.17e-06	9.35e-05	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—lung cancer	8.06e-06	9.22e-05	CcSEcCtD
Dasatinib—Nausea—Methotrexate—lung cancer	7.81e-06	8.94e-05	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—lung cancer	7.79e-06	8.92e-05	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—lung cancer	7.53e-06	8.62e-05	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—lung cancer	7.24e-06	8.29e-05	CcSEcCtD
Dasatinib—Rash—Doxorubicin—lung cancer	7.18e-06	8.22e-05	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—lung cancer	7.17e-06	8.21e-05	CcSEcCtD
Dasatinib—Headache—Doxorubicin—lung cancer	7.13e-06	8.17e-05	CcSEcCtD
Dasatinib—Nausea—Doxorubicin—lung cancer	6.76e-06	7.74e-05	CcSEcCtD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—lung cancer	2.41e-07	2.37e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.41e-07	2.36e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—lung cancer	2.41e-07	2.36e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—lung cancer	2.4e-07	2.36e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—lung cancer	2.4e-07	2.35e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—lung cancer	2.39e-07	2.35e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—STAT3—lung cancer	2.39e-07	2.35e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—lung cancer	2.39e-07	2.35e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—SRC—lung cancer	2.39e-07	2.34e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—lung cancer	2.39e-07	2.34e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—lung cancer	2.39e-07	2.34e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCL8—lung cancer	2.38e-07	2.34e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NRAS—lung cancer	2.38e-07	2.34e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—lung cancer	2.38e-07	2.34e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—lung cancer	2.38e-07	2.34e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTP1—lung cancer	2.37e-07	2.33e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—EP300—lung cancer	2.37e-07	2.33e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—lung cancer	2.37e-07	2.32e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EP300—lung cancer	2.36e-07	2.32e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CD—lung cancer	2.36e-07	2.32e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—lung cancer	2.36e-07	2.32e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CREBBP—lung cancer	2.35e-07	2.31e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—lung cancer	2.35e-07	2.31e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—PIK3CA—lung cancer	2.34e-07	2.3e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STAT3—lung cancer	2.34e-07	2.3e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EP300—lung cancer	2.33e-07	2.29e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NRAS—lung cancer	2.33e-07	2.29e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ALB—lung cancer	2.33e-07	2.29e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—lung cancer	2.33e-07	2.29e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—lung cancer	2.33e-07	2.28e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—lung cancer	2.32e-07	2.28e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MAPK3—lung cancer	2.32e-07	2.27e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CAT—lung cancer	2.31e-07	2.27e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—lung cancer	2.3e-07	2.26e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STAT3—lung cancer	2.3e-07	2.26e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—SRC—lung cancer	2.3e-07	2.26e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NRAS—lung cancer	2.3e-07	2.26e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—lung cancer	2.3e-07	2.26e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.3e-07	2.25e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—lung cancer	2.3e-07	2.25e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—lung cancer	2.29e-07	2.25e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK3—lung cancer	2.28e-07	2.24e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CASP3—lung cancer	2.28e-07	2.24e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—lung cancer	2.28e-07	2.24e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2—lung cancer	2.28e-07	2.24e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—lung cancer	2.28e-07	2.24e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—SRC—lung cancer	2.27e-07	2.23e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MDM2—lung cancer	2.26e-07	2.22e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—lung cancer	2.25e-07	2.21e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—lung cancer	2.25e-07	2.21e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RAF1—lung cancer	2.25e-07	2.21e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ABCB1—lung cancer	2.25e-07	2.2e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—lung cancer	2.24e-07	2.2e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK3—lung cancer	2.23e-07	2.19e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CD—lung cancer	2.23e-07	2.19e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB2—lung cancer	2.23e-07	2.18e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—APOA1—lung cancer	2.22e-07	2.18e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—lung cancer	2.22e-07	2.18e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP2E1—lung cancer	2.22e-07	2.18e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—lung cancer	2.22e-07	2.18e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STAT3—lung cancer	2.22e-07	2.18e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—JUN—lung cancer	2.22e-07	2.18e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NRAS—lung cancer	2.21e-07	2.17e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—lung cancer	2.21e-07	2.17e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—lung cancer	2.21e-07	2.17e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PIK3CA—lung cancer	2.21e-07	2.17e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TYMS—lung cancer	2.21e-07	2.17e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ALB—lung cancer	2.2e-07	2.16e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—lung cancer	2.2e-07	2.16e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK3—lung cancer	2.2e-07	2.16e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—lung cancer	2.2e-07	2.16e-06	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—lung cancer	2.2e-07	2.16e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CB—lung cancer	2.2e-07	2.16e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MTOR—lung cancer	2.2e-07	2.16e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NQO1—lung cancer	2.2e-07	2.16e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—lung cancer	2.19e-07	2.15e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STAT3—lung cancer	2.19e-07	2.15e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NRAS—lung cancer	2.18e-07	2.14e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—lung cancer	2.18e-07	2.14e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—lung cancer	2.18e-07	2.14e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTM1—lung cancer	2.18e-07	2.14e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—lung cancer	2.17e-07	2.13e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—lung cancer	2.17e-07	2.13e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—lung cancer	2.16e-07	2.12e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PIK3CA—lung cancer	2.16e-07	2.12e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—lung cancer	2.16e-07	2.12e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1A—lung cancer	2.15e-07	2.11e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTEN—lung cancer	2.14e-07	2.1e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—lung cancer	2.14e-07	2.1e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—lung cancer	2.14e-07	2.1e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—lung cancer	2.13e-07	2.09e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—lung cancer	2.12e-07	2.08e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK3—lung cancer	2.12e-07	2.08e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL8—lung cancer	2.11e-07	2.07e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—lung cancer	2.09e-07	2.05e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CA—lung cancer	2.09e-07	2.05e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK3—lung cancer	2.09e-07	2.05e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—lung cancer	2.08e-07	2.04e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—lung cancer	2.07e-07	2.03e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PIK3CA—lung cancer	2.07e-07	2.03e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP1A1—lung cancer	2.07e-07	2.03e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—lung cancer	2.06e-07	2.02e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CB—lung cancer	2.06e-07	2.02e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—lung cancer	2.05e-07	2.01e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ERCC2—lung cancer	2.05e-07	2.01e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—lung cancer	2.04e-07	2.01e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EP300—lung cancer	2.04e-07	2.01e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—lung cancer	2.04e-07	2e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—lung cancer	2.03e-07	2e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CG—lung cancer	2.03e-07	1.99e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—lung cancer	2.02e-07	1.99e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—lung cancer	2.02e-07	1.98e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CASP3—lung cancer	2.02e-07	1.98e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2—lung cancer	2.02e-07	1.98e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—lung cancer	2.02e-07	1.98e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—lung cancer	2.01e-07	1.98e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—lung cancer	2.01e-07	1.97e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—lung cancer	2e-07	1.96e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—lung cancer	1.99e-07	1.95e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SRC—lung cancer	1.99e-07	1.95e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—STK11—lung cancer	1.98e-07	1.94e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—lung cancer	1.98e-07	1.94e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—lung cancer	1.97e-07	1.93e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—JUN—lung cancer	1.96e-07	1.93e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—lung cancer	1.96e-07	1.92e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CB—lung cancer	1.95e-07	1.91e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—lung cancer	1.94e-07	1.9e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—lung cancer	1.94e-07	1.9e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—POMC—lung cancer	1.93e-07	1.9e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—lung cancer	1.93e-07	1.89e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CA—lung cancer	1.93e-07	1.89e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STAT3—lung cancer	1.92e-07	1.88e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—lung cancer	1.92e-07	1.88e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NRAS—lung cancer	1.91e-07	1.88e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—lung cancer	1.91e-07	1.88e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PIK3CA—lung cancer	1.91e-07	1.88e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—lung cancer	1.91e-07	1.88e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—lung cancer	1.91e-07	1.87e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—lung cancer	1.9e-07	1.87e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1A—lung cancer	1.9e-07	1.87e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTEN—lung cancer	1.9e-07	1.86e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CA—lung cancer	1.88e-07	1.85e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CREBBP—lung cancer	1.88e-07	1.85e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—lung cancer	1.88e-07	1.85e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—lung cancer	1.85e-07	1.82e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CA—lung cancer	1.85e-07	1.81e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—lung cancer	1.83e-07	1.8e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK3—lung cancer	1.83e-07	1.8e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTP1—lung cancer	1.83e-07	1.8e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—lung cancer	1.82e-07	1.79e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CA—lung cancer	1.82e-07	1.78e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EP300—lung cancer	1.81e-07	1.78e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—lung cancer	1.81e-07	1.77e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—lung cancer	1.79e-07	1.75e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CD—lung cancer	1.78e-07	1.75e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CAT—lung cancer	1.78e-07	1.75e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—lung cancer	1.78e-07	1.75e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTEN—lung cancer	1.78e-07	1.75e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—APOA1—lung cancer	1.77e-07	1.74e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—lung cancer	1.77e-07	1.74e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—lung cancer	1.76e-07	1.73e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ALB—lung cancer	1.76e-07	1.73e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—lung cancer	1.76e-07	1.73e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CA—lung cancer	1.75e-07	1.72e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CA—lung cancer	1.75e-07	1.72e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—lung cancer	1.74e-07	1.71e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—lung cancer	1.74e-07	1.71e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ABCB1—lung cancer	1.73e-07	1.7e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CA—lung cancer	1.73e-07	1.7e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—lung cancer	1.71e-07	1.68e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—lung cancer	1.71e-07	1.68e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—lung cancer	1.71e-07	1.68e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TYMS—lung cancer	1.7e-07	1.67e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.7e-07	1.67e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STAT3—lung cancer	1.7e-07	1.67e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—EP300—lung cancer	1.7e-07	1.67e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NRAS—lung cancer	1.69e-07	1.66e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—lung cancer	1.69e-07	1.66e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—lung cancer	1.69e-07	1.66e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—lung cancer	1.69e-07	1.66e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTM1—lung cancer	1.68e-07	1.65e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTEN—lung cancer	1.68e-07	1.65e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—lung cancer	1.68e-07	1.65e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—lung cancer	1.67e-07	1.64e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—lung cancer	1.67e-07	1.64e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—lung cancer	1.65e-07	1.62e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—lung cancer	1.63e-07	1.6e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK3—lung cancer	1.62e-07	1.59e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CG—lung cancer	1.62e-07	1.59e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—lung cancer	1.62e-07	1.59e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—lung cancer	1.61e-07	1.58e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—EP300—lung cancer	1.6e-07	1.57e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—lung cancer	1.6e-07	1.57e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP1A1—lung cancer	1.6e-07	1.57e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ERCC2—lung cancer	1.58e-07	1.55e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—lung cancer	1.58e-07	1.55e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—lung cancer	1.57e-07	1.54e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—lung cancer	1.56e-07	1.53e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CB—lung cancer	1.55e-07	1.53e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—lung cancer	1.55e-07	1.52e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—lung cancer	1.54e-07	1.51e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—POMC—lung cancer	1.54e-07	1.51e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—lung cancer	1.54e-07	1.51e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—lung cancer	1.54e-07	1.51e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—lung cancer	1.53e-07	1.5e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CA—lung cancer	1.51e-07	1.48e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—lung cancer	1.51e-07	1.48e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CREBBP—lung cancer	1.5e-07	1.47e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—lung cancer	1.48e-07	1.46e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—lung cancer	1.46e-07	1.44e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—lung cancer	1.46e-07	1.43e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—lung cancer	1.43e-07	1.41e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—lung cancer	1.43e-07	1.4e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CD—lung cancer	1.42e-07	1.4e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—lung cancer	1.41e-07	1.38e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ALB—lung cancer	1.41e-07	1.38e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—lung cancer	1.4e-07	1.37e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—APOA1—lung cancer	1.37e-07	1.34e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTEN—lung cancer	1.34e-07	1.32e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—lung cancer	1.34e-07	1.31e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CA—lung cancer	1.34e-07	1.31e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—lung cancer	1.3e-07	1.27e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—EP300—lung cancer	1.28e-07	1.26e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CA—lung cancer	1.26e-07	1.23e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CG—lung cancer	1.25e-07	1.23e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CB—lung cancer	1.24e-07	1.22e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—lung cancer	1.24e-07	1.22e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—lung cancer	1.24e-07	1.21e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—lung cancer	1.23e-07	1.21e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—POMC—lung cancer	1.19e-07	1.17e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CA—lung cancer	1.19e-07	1.16e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—lung cancer	1.19e-07	1.16e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CREBBP—lung cancer	1.16e-07	1.14e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CD—lung cancer	1.1e-07	1.08e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—lung cancer	1.09e-07	1.07e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ALB—lung cancer	1.08e-07	1.06e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTEN—lung cancer	1.07e-07	1.05e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—lung cancer	1.03e-07	1.01e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—EP300—lung cancer	1.02e-07	1e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—lung cancer	9.69e-08	9.51e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CB—lung cancer	9.57e-08	9.4e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—lung cancer	9.49e-08	9.31e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CA—lung cancer	9.47e-08	9.3e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTEN—lung cancer	8.27e-08	8.12e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—EP300—lung cancer	7.89e-08	7.75e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—lung cancer	7.74e-08	7.6e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CA—lung cancer	7.56e-08	7.42e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—lung cancer	6.18e-08	6.07e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CA—lung cancer	5.84e-08	5.73e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—lung cancer	4.77e-08	4.68e-07	CbGpPWpGaD
